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Abstract
Calcitonin receptor-like receptor (CRLR) constitutes either a CGRP receptor when complexed with receptor activity-
modifying protein 1 (RAMP1) or an adrenomedullin receptor when complexed with RAMP2 or RAMP3. RAMP proteins
modify the glycosylation status of CRLR and determine their receptor specificity; when treated with tunicamycin, a
glycosylation inhibitor, CHO-K1 cells constitutively expressing both RAMP2 and CRLR lost the capacity to bind
adrenomedullin. Similarly, in HEK293 EBNA cells constitutively expressing RAMP1/CRLR receptor complex CGRP
binding was remarkably inhibited. Whichever RAMP protein was co-expressing with CRLR, the ligand binding was sensitive
to tunicamycin. There are three putative Asn-linked glycosylation sites in the extracellular, amino terminal domain of CRLR
at positions 66, 118 and 123. Analysis of CRLR mutants in which Gln was substituted for selected Asn residues showed that
glycosylation of Asn123 is required for both the binding of adrenomedullin and the transduction of its signal. Substituting
Asn66 or Asn118 had no effect. FACS analysis of cells expressing FLAG-tagged CRLRs showed that disrupting Asn-linked
glycosylation severely affected the transport of the CRLR protein to the cell surface on N66/118/123Q mutant, and slightly
reduced the level of the cell surface expression of N123Q mutant compared with wild-type CRLR. But other single mutants
(N66Q, N118Q) had no effect for other single mutants. Our data shows that glycosylation of Asn66 and Asn118 is not
essential for ligand binding, signal transduction and cell surface expression, and Asn123 is important for ligand binding and
signal transduction rather than cell surface expression. It thus appears that glycosylation of Asn123 is required for CRLR to
assume the appropriate conformation on the cell surface through its interaction with RAMPs. ß 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Adrenomedullin, which is isolated from human
pheochromocytoma, is a member of the calcitonin
gene-related peptide (CGRP) family [1]. It is known
to be potently hypotensive in rat and to evoke in-
creases in the levels of cyclic AMP (cAMP) within
mammalian endothelial, smooth muscle and mesan-
gial cells [1^6]. Recently, McLatchie et al. reported
that the calcitonin receptor-like receptor (CRLR)
could function as either a CGRP receptor or an
adrenomedullin receptor, depending on the type of
receptor activity-modifying proteins (RAMPs) ^
members of a new family of single-transmembrane-
0167-4889 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 0 1 ) 0 0 1 0 0 - 8
* Corresponding author. Fax: +81-6-6382-2598;
E-mail : tsuneaki.sakata@shionogi.co.jp
BBAMCR 14755 22-5-01
Biochimica et Biophysica Acta 1539 (2001) 131^139
www.bba-direct.com
domain proteins ^ expressed [7] : CRLR generates a
CGRP receptor with RAMP1, whereas it generates
an adrenomedullin receptor with either RAMP2 or
RAMP3. We observed, for example, that in human
vascular endothelial and smooth muscle cells CRLR
and RAMP2 generate a functional adrenomedullin
receptor [8].
RAMP proteins modify receptor speci¢city by reg-
ulating the glycosylation status of CRLR: RAMP2
and RAMP3 modulate CRLR core glycosylation,
while RAMP1 modulates the terminal glycosylation
[7]. The amino terminus of CRLR is situated in the
extracellular domain and has three potential Asn-
linked glycosylation sites (at positions 66, 118, and
123) [9,10]. On the other hand, no putative Asn-
linked glycosylation site consists in RAMP1 and a
single putative Asn-linked glycosylation site, which is
respectively conserved among human, mouse, and
rat, is situated in RAMP2 and RAMP3 [7,11]. And
Aldecoa et al. demonstrated that RAMP2 was glyco-
sylated in Schneider 2 insect cell [12]. RAMP2 and
RAMP3 have putative Asn-linked glycosylation sites
and RAMP1 has no putative site. In the present
study, in spite of glycosylation our data shows that
of RAMP, receptor activity of CRLR/RAMPs com-
plex was inhibited tunicamycin and substitution of
Asn123 in CRLR fully disrupted receptor activity.
And we determined that the glycosylation of Asn
at position 123 is required for generating a functional
adrenomedullin receptor.
2. Materials and methods
2.1. Materials
Dulbecco’s modi¢ed Eagle’s medium (DMEM)
was purchased from Nihon Seiken (Kyoto, Japan).
MEM-K was purchased from Gibco BRL (Grand
Island, NY). Bovine serum albumin (BSA) and 3-
isobutyl-1-methylxanthine (IBMX) were from Sigma
Chemical (St. Louis, MO). All other reagents were
from Nacalai Tesque (Kyoto, Japan).
2.2. Plasmids
All CRLR-related plasmids were constructed from
CRLR cDNA cloned into pcDNA3.1(+) expression
vector (Invitrogen, Carlsbad, CA), as described pre-
viously [8]. FLAG epitope-tagged CRLRs were con-
structed by cloning mature CRLR into pFLAG-
CMV1 vector (Kodak, New Haven, CT). Three
kinds of RAMP plasmids were cloned into pIRES-
puro vector carrying the puromycin-resistance gene
(Clontech, Palo Alto, CA) using the NotI restriction
site.
2.3. Cell culture and cDNA transfection
CHO-K1, HEK293 EBNA and HEK293 cells were
cultured in MEM-K and DMEM supplemented with
10% fetal bovine serum, respectively, and maintained
at 37‡C under an atmosphere of 95% air/5% CO2.
Clones expressing both CRLR and each RAMP or
only RAMP2 were selected by culturing cells trans-
fected with plasmids encoding CRLR and/or
RAMP2 and a selection marker (pDREF-CRLR-
EBNA-Hyg [8] and pRAMPs-IRES-puro) in the
presence of hygromycin (Wako Chemicals, Osaka,
Japan) or puromycin (Clontech), respectively.
For transient transfection, HEK293 cells were
plated to a density of 1^5U105 cells/well in 24-well
plates and transfected with 1 Wg plasmid/well using
LipofectAmine Plus according to the manufacturer’s
instructions (Gibco BRL). In cases where intracellu-
lar cAMP was measured, the normal culture medium
was replaced with serum-free medium 24 h after
transfection, and the transfectants incubated for an
additional 24 h.
2.4. Preparation of membrane fractions
Harvested cells were washed with ice-cold bu¡er
(20 mM HEPES^NaOH (pH 7.4) containing Com-
plete (Roche Diagnostics, Mannheim, Germany)),
suspended in the same bu¡er, homogenized, and cen-
trifuged at 1000Ug for 30 min at 4‡C. The super-
natant was then centrifuged again at 10 000Ug for 30
min at 4‡C, and the resultant pellet (membrane frac-
tion) was resuspended in the bu¡er. The protein con-
centration in each sample was measured by the Brad-
ford method (Bio-Rad, Hercules, CA).
2.5. Binding assays
Adrenomedullin or CGRP binding to wild-type
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and mutant CRLRs in the membrane fraction of
HEK293 transfectants was assessed using a scintilla-
tion proximity assay system (SPA, Amersham^Phar-
macia, Little Chalfont, UK), as described previously
[7,13]. Brie£y, samples of the membrane fraction
(equivalent to a protein concentration of 10 Wg for
adrenomedullin binding or 30 Wg for CGRP bind-
ing), pre-coupled to 1 mg of PVT-WGA-SPA beads,
were placed the wells of a 96-well microplate contain-
ing 100 Wl of assay solution (50 mM HEPES (pH
7.4), 10 mM MgCl2, 1 mM EDTA, 0.5% BSA and
100 pM [125I]rat adrenomedullin or [125I]human
CGRP (Amersham^Pharmacia)) and incubated for
2 h at 4‡C for adrenomedullin binding or at room
temperature for CGRP binding. Radioactivity in the
membrane fraction was then counted using a micro-L
counter (Amersham^Pharmacia, Wallac). Non-spe-
ci¢c binding was determined by incubating the mem-
brane fraction in the presence of 1 WM unlabeled rat
adrenomedullin (Peptide Institute, Osaka, Japan) for
adrenomedullin binding or human CGRP (Peptide
Institute) for CGRP binding; speci¢c binding was
then calculated by subtracting the non-speci¢c from
the total binding.
2.6. Measurement of cAMP
Intracellular cAMP was measured as reported pre-
viously [14]. Brie£y, cells were washed twice with
Hank’s balanced salt solution containing 20 mM
HEPES (pH 7.4), 0.1% bovine serum albumin and
0.5 mM IBMX, and then incubated in the same so-
lution for 15 min in the presence or absence of li-
gand. Thereafter, the cells were lysed in lysis bu¡er
1B from the Biotrack cAMP EIA assay kit (Amer-
sham^Pharmacia), and cAMP was measured accord-
ing to the manufacturer’s instructions.
2.7. Flow cytometry
HEK293 cells were transiently transfected with the
respective cDNAs encoding FLAG-tagged wild-type
CRLR (FLAG-CRLR) or one of four CRLRs con-
taining mutations at the Asn-linked glycosylation
sites (FLAG-N66Q, FLAG-N118Q, FLAG-N123Q
and FLAG-N66/118/123Q CRLR). After harvesting
2 days later, the cells were washed twice with phos-
phate-bu¡ered saline (PBS) resuspended in PBS con-
taining 0.1% BSA, and incubated for 1 h on ice with
anti-FLAG antibody (M2; 1:20 dilution). The cells
were then washed twice with PBS+0.1% BSA, incu-
bated for 1 h in the dark with £uorescein isothiocya-
nate (FITC)-conjugated anti-mouse IgG (Dako,
Glostrup, Denmark), washed twice more with
PBS+0.1% BSA, and resuspended in the same bu¡er.
Cell sorting was performed using an EPICS-XL
(Coulter Corp., Hialeah, FL); 30 000 cells were
sorted in each experiment.
2.8. Statistics
Values are expressed as means þ S.D. The statisti-
cal signi¢cance of di¡erences among cells was eval-
uated using unpaired analysis of variance and Stu-
dents’ t-tests. Values of P6 0.05 were considered
signi¢cant. All experiments were performed inde-
pendently at least repeated three times.
3. Results
3.1. Both CGRP and adrenomedullin are not bound to
membranes treated with tunicamycin
To study the e¡ect of the glycosylation on adreno-
medullin receptor biology, we ¢rst compared the ef-
fects of tunicamycin, a glycosylation inhibitor, on
HEK293 EBNA cells transfected with CRLR and
RAMP1 (293E/CRLR/RAMP1) and on CHO-K1
cells transfected with CRLR and RAMP2 cDNAs
(CHO-K1/CRLR/RAMP2), and on respective un-
transfected cells. After exposing the cells to a max-
imally e¡ective concentration of tunicamycin for 48 h
and preparing membrane fractions as described in
Section 2, we measured the level of CGRP binding
to RAMP1/CRLR and the level of adrenomedullin
binding to RAMP2/CRLR. As shown in Fig. 1, ex-
pression of CRLR and RAMP1 markedly enhanced
CGRP binding to 293 EBNA cell membrane and
expression of CRLR and RAMP2 does. This e¡ect
was completely blocked by tunicamycin, which re-
duced binding in both 293E/CRLR/RAMP1 and
CHO-K1/CRLR/RAMP2 cells to the levels seen in
respective control cells. Adrenomedullin binding to
HEK293 cells constitutively expressing CRLR/
RAMP3 complex was lost by the e¡ect of tunicamy-
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cin (data not shown). In 293E/CRLR/RAMP1, tuni-
camycin severely reduced CGRP binding. Both li-
gand bindings to membranes extracted from control
cells was una¡ected by tunicamycin. Because there is
no glycosylation site in RAMP1, glycosylation of
CRLR thus appears to be essential for both ligand
bindings to the CRLR/RAMP receptor complexes.
3.2. N-Glycosylation of Asn at position 123 is required
for ligand binding
Three putative Asn-glycosylation sites are situated
Fig. 1. E¡ects of tunicamycin on ligand binding to CRLR. (A)
[125I]Human CGRP binding to HEK293EBNA cell membranes
was assayed. (B) [125I]Rat adrenomedullin binding to CHO-K1
cell membranes was assayed. Membrane fractions were pre-
pared from control and tunicamycin-treated (6.4 Wg/ml for 48
h) transfectants constitutively expressing CRLR and each
RAMP and from untransfected control cells, as described in
Section 2. Closed bar represents total binding and open bar
represents non-speci¢c binding.
Fig. 2. Ligand binding to CRLRs containing NCQ substitu-
tion mutations at Asn-linked glycosylation sites. HEK293 cells
were transiently co-transfected with RAMP1 (A) or RAMP2
(B) and wild-type CRLR or one of four mutant CRLRs substi-
tuted at Asn66 (N66Q), Asn118 (N118Q), Asn123 (N123Q) or
all three (N66/118/123Q). Thereafter, cell membranes were pre-
pared and binding assays were performed as in Fig. 1. Closed
bar represents total binding and open bar represents non-specif-
ic binding.
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in the amino terminal of human CRLR, at positions
66, 118 and 123. To investigate which of these sites is
necessary for adrenomedullin binding, a group of
mutant CRLRs were constructed by substituting
Gln (Q) for Asn (N) at one or all of the glycosylation
sites: N66Q, N118Q, N123Q and N66/118/123Q
CRLR. HEK293 cells were then transiently co-trans-
fected with RAMP1 or RAMP2 and one of the mu-
tant CRLRs, after which all of the transfectants
showed the same level of mRNA expression by
northern analysis (data not shown). Membrane frac-
tions were prepared 48 h after transfection, and bind-
ing assays were performed. Speci¢c binding to mem-
branes extracted from cells expressing the N123Q
and N66/118/123Q CRLR mutants was the same as
that to membranes from untransfected cells (Fig. 2).
In contrast, CGRP or adrenomedullin binding to
membranes extracted from cells expressing either
the N66Q or N118Q CRLR mutant was the same
as that to membranes from cells expressing wild-
type CRLR.
When expressed with RAMP3, the N123Q or N66/
118/123Q mutant had similar inhibitory e¡ects on
adrenomedullin binding (data not shown).
3.3. N-Glycosylation of Asn123 is important for
ligand signaling of cAMP
To assess the importance of glycosylation of
Asn123 for adrenomedullin-evoked increases in in-
tracellular cAMP, HEK293 cells were co-transfected
for 48 h with RAMP1 or RAMP2 and one of the
four CRLR mutants, after which intracellular cAMP
was measured. As in untransfected cells, cyclic AMP
levels in cells expressing the N66/118/123Q CRLR
mutant were una¡ected by CGRP or adrenomedul-
lin, even at a concentration of 100 nM (Fig. 3A,B).
Expression of the N123Q mutant was also pro-
foundly inhibitory, though a small but signi¢cant
6
Fig. 3. E¡ect of ligand on intracellular cAMP levels in HEK
293 cells expressing each RAMP and wild-type or mutant
CRLRs. HEK293 cells transiently transfected with RAMP1 and
either wild-type (a), N66Q (O), N118Q (R), N123Q (E), N66/
118/123Q (F) CRLR or mock (b) were stimulated with 0^1037
M CGRP (A), with RAMP2 and either wild-type or above
CRLR mutants with 0^1037 M adrenomedullin (B), and with
RAMP2 and either wild-type (a), N66/118Q (O), N66/123Q
(R), N118/123Q (E), N123Q (F), or mock (b) for 15 min at
37‡C. Intracellular cAMP levels were then measured using a
cAMP EIA kit. The data are expressed as mean þ S.D.
*P6 0.05 versus basal levels.
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increase in cAMP was elicited by 100 nM adrenome-
dullin. In contrast, CGRP or adrenomedullin elicited
concentration-dependent increases in cAMP in cells
expressing the N66Q or N118Q mutant that were
indistinguishable from those elicited in cells express-
ing wild-type CRLR. In these cells, signi¢cant in-
creases in cAMP were ¢rst seen at an adrenomedullin
concentration of 0.1 nM, a concentration 10 000
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times lower than that required to elicit an e¡ect in
cells expressing the N123Q mutant.
Consistent with the binding data, lower concen-
trations of adrenomedullin had no e¡ect on cAMP
levels in cells expressing RAMP3 and either the
N123Q or N66/118/123Q CRLR mutant (data not
shown).
We attempted to investigate intracellular cAMP
increase in further new CRLR mutants: N66/118Q,
N66/123Q, N118/123Q, when adrenomedullin
evoked. As the results, N66/118Q had no e¡ect
and, in contrast, other double mutants were inhibi-
tory (Fig. 3C).
3.4. Delivery of N123Q CRLR to the cell surface
To assess the membrane topology of the CRLR
mutants, isoforms containing an amino terminal
FLAG epitope were constructed and transfected
into HEK293 cells transiently co-transfected
RAMP1 or HEK293 cells constitutively expressing
RAMP2. No di¡erences in the expression, binding
or signaling were observed between untagged and
FLAG-tagged CRLR derivatives (data not shown).
Moreover, FACS analysis of these cells demon-
strated similar levels of antibody binding to FLAG-
tagged, wild-type CRLR and to the N66Q and
N118Q mutants (data not shown). The antibody
binding to N123Q mutant CRLR was lower than
wild-type CRLR and N66/118/123Q CRLR was
markedly reduced (Fig. 4). N123Q CRLR thus ap-
pear to be transported to the cell surface to the some
extent; If the e⁄ciencies of transfection were equal
to all plasmid constructs, the level of antibody bind-
ing in N123Q mutant was 84% (RAMP1/CRLR),
40% (RAMP2/CRLR) and 50% (RAMP1/CRLR)
18% (RAMP2/CRLR) in N66/118/123Q as wild
type.
4. Discussion
Most G-protein-coupled receptors (GPCRs) are
glycosylated [15], though the speci¢c function of
the glycosylation may vary considerably. By inhibit-
ing glycosylation during GPCR synthesis or by enzy-
matic deglycosylation of expressed receptors, investi-
gators have been able to determine that, in some
GPCRs, glycosylation plays a role in receptor trans-
port [16] and function [17^20], while in others glyco-
sylation serves no apparent function [21^25]. Our
demonstration that tunicamycin blocks CGRP and
adrenomedullin binding con¢rms that for CRLR gly-
cosylation is required for the receptor to function
properly.
It was recently shown that the adrenomedullin re-
ceptor exists as a complex of CRLR and RAMP2 or
RAMP3 and simultaneously CGRP receptor consists
of CRLR and RAMP1, and that the amino terminal
of RAMPs is critical to the glycosylation state and
ligand binding of CRLR [7,26,27]. When co-ex-
pressed with RAMP2 or RAMP3, CRLR is core-gly-
cosylated, whereas CRLR co-expressed with RAMP1
is terminal-glycosylated [7]. Several putative Asn-
linked glycosylation sites are situated in RAMP2
and RAMP3 but no site is situated in RAMP1.
One nearest to the carboxyl terminus out of these
sites is conserved not only among mouse, rat, and
human but also between RAMP2 and RAMP3
[7,11]. There are three putative Asn-linked glycosyl-
ation sites at positions 66, 118 and 123 in the amino
terminus of human CRLR [9,10]; it was unknown
which site was most important for the cell surface
delivery of CRLR, the binding of CGRP and adre-
nomedullin and the transduction of its signal. Our
analysis of mutant CRLRs showed that Asn66 and
Asn118 would be the glycosylation sites not essential
and Asn123 is the glycosylation site essential for
Fig. 4. Delivery of FLAG-tagged wild-type and mutant CRLRs to the cell surface. HEK293 cells co-transfected with RAMP1 (A^D)
or constitutively expressing RAMP2 (E^H) were transiently transfected with cDNA encoding FLAG-tagged wild-type or mutant
CRLR, after which the cells were incubated ¢rst with mouse monoclonal anti-FLAG antibody (M2) and then with FITC-conjugated
anti-mouse IgG. FACS sorting was then performed on more than 30 000 cells in each experiment. Sham-transfected cells showed no
signi¢cant £uorescence (data not shown). (A,E) Control, HEK293 cells expressing RAMP1 (293/RAMP1) (A) or HEK293 cells ex-
pressing RAMP2 (293/RAMP2) (E). (B,F) 293/RAMP1 (B) or 293/RAMP2 (F) cells transiently transfected with FLAG-wild-type
CRLR. (C,G) 293/RAMP1 (C) or 293/RAMP2 (G) cells transfected with FLAG-N66/118/123Q CRLR. (D,H) 293/RAMP1 (D) or
293/RAMP2 (H) cells transfected with FLAG-N123Q CRLR.
6
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binding CGRP and adrenomedullin and transducing
its signal. Flow cytometry of cells expressing either
RAMP1 or RAMP2 and FLAG-tagged CRLR
showed that substitution of a Gln residue for
Asn123 somewhat a¡ected transport of the CRLR
protein to the cell surface. Taken together, these ¢nd-
ings indicate that disruption of cell surface glycosyl-
ation at Asn123 of CRLR alters the structure or
the receptor, making it unable to bind CGRP or
adrenomedullin rather than to deliver to the cell sur-
face.
Human calcitonin receptor (hCTR) generates an
amylin receptor with RAMP1 or RAMP3 [28^33].
In addition, RAMP1 confers CGRP binding the cal-
citonin receptor [33]. Subtypes of hCTR may contain
three or four amino-terminal, Asn-linked glycosyla-
tion sites in the extracellular domain [34]. Of these
subtypes, hCTR3, which is produced by alternative
RNA splicing and lacks the ¢rst 47 amino acids,
including a potential Asn-linked glycosylation site,
contains three potential glycosylation sites [35],
among which Asn83 is the most important for the
binding of calcitonin and the transduction of its sig-
nal [20].
It has been proposed that both glycosylation state
and the amino termini of RAMP proteins determine
the pharmacology of RAMP-coupled receptors, with
RAMP determining the receptor speci¢city either di-
rectly or indirectly [30]. Experiments carried out us-
ing chimeric RAMP proteins, comprised of the trans-
membrane and cytosolic domains of RAMP1 and the
extracellular amino terminus of RAMP2 (RAMP2/1)
and vice versa (RAMP1/2), demonstrated that co-ex-
pression of the RAMP2/1 chimera with CRLR pro-
duced responses similar to those seen with RAMP2
alone, which suggests that the amino termini of
RAMPs are crucial for determining the activity and
receptor speci¢city of CRLRs [26,28]. Furthermore,
it was shown that 125I-labeled ligand cross-linked
with rCRLR and RAMP protein in Schneider insect
cells and RAMP protein appeared at the cell surface
in close association with CRLR [12]. It is directly
indicated that ligand interacted with both amino-ter-
minus of RAMP and extracellular domain of CRLR.
We therefore postulate that CRLR/RAMP com-
plexes are formed principally via the interaction of
the transmembrane domain of CRLR and cytosolic
carboxyl terminus of RAMP; interaction between
the amino terminus of RAMP and the extracellular
domain of CRLR determines receptor speci¢city.
Perhaps glycosylation of Asn123 produces a confor-
mational change in CRLR enabling its interaction
with RAMP, after which the amino terminus of
RAMP may interact with the Asn-glycosylated ami-
no terminal of CRLR, and thereby was concerned
with creating a peptide binding-pocket.
Very recently, Bu«hlmann et al. reported that gly-
cosylation of two CRLR at Asn66 or Asn118 is im-
portant for cell surface expression [36], although
CRLR protein from a CRLR cDNA used in their
report is six amino acid residues shorter than that of
our report. In their report it was shown that a single
substitution of either Asn66, Asn118, or Asn123
caused remarkable reduction of CGRP or adrenome-
dullin binding but did not a¡ect transport to the cell
surface. Also, the double mutant of Asn66 and
Asn118 inhibited the binding and cell surface expres-
sion. According to analysis of Asn-linked glycosyla-
tion of myc-CRLR and mutant on western blotting
in the absence or presence of RAMPs or N-glyco-
sides F, it is suggested that Asn123 of myc-CRLR
is required for ligand recognition in the presence of
RAMPs and not required for Asn-linked glycosyla-
tion and cell surface delivery of the hCRLR. Our
data showed that single substitution of Asn66 or
Asn118 did not a¡ect cell surface expression nor re-
ceptor function, whichever RAMP was expressed,
and that both Asn66 and Asn118 were disrupted,
signal transduction of adrenomedullin receptor being
apparently normal, comparable to wild type. In con-
trast, disruption of Asn123 in our data led to some
reduction of transport to the cell surface, and com-
pletely inhibited ligand and signal transduction of
CRLR. The reason why this di¡erence/discrepancy
between these two results exists is unknown. It may
be due to substitution of Asn to Gln or Thr, due to
plasmids used (for example promoter, transfection
e⁄ciency and so on), or due to host cells for trans-
fection. However, Asn123 was important in recogniz-
ing ligand in the presence of RAMPs corresponding
with our data. In the future, further investigation is
required to deepen the understanding of the relation
between RAMP function and glycosylation of
CRLR.
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